Pharmacogenomic and drug interaction risk associations with hospital length of stay among Medicare Advantage members with COVID-19

Kristine Ashcraft, MBA,^{1*} Chad Moretz, ScD¹, Chantelle Schenning, PhD,¹ Susan Rojahn, PhD,¹ Kae Vines Tanudtanud, MS,² Gwyn Omar Magoncia, BS,² Justine Reyes, BS,² Bernardo Marquez, PhD,² Yinglong Guo, MS,² Elif Tokar Erdemir, PhD,² Taryn O. Hall, MPH, PhD²

¹Invitae Corporation, 1400 16th St, San Francisco, CA 94103

²OptumLabs at UnitedHealth Group, 5995 Opus Parkway, Minnetonka, MN 55343

*Corresponding Author: Kristine Ashcraft, Invitae Corporation, 710 2nd Ave, Ste. 600, Seattle, WA 98104. Phone: (206) 930-9062. Email: kristine.ashcraft@invitae.com

Manuscript word count: 2,975

Keywords: COVID-19, pharmacogenomics, medication management, hospitalization, precision medicine, length of stay, healthcare administration, healthcare costs

List of abbreviations:

COVID-19: Coronavirus-induced disease 2019

CPIC: Clinical Pharmacogenetics Implementation Consortium

DDI: Drug-drug interaction

FDA: U.S. Food and Drug Administration

HCC: hierarchical conditions categories

LOS: Length of stay

PIP: Pharmacogenetic interaction probability

RAF: Risk adjustment factor

SNP: Special needs plan

Key Points

Question: What is the impact of unmanaged pharmacogenomic risk among patients hospitalized with COVID-19?

Findings: Among 6,025 patients hospitalized with COVID-19, those with greater unmanaged pharmacogenomic risk for adverse drug reactions had longer hospital stays than those with lower risk, both within the entire cohort and within groups matched by number and type of chronic conditions.

Meaning: Preemptive pharmacogenomic testing may shorten hospital stay by reducing adverse drug reactions among seriously ill patients and more broadly improve patient risk classification, care utilization predictions, and health system performance.

Abstract

Importance: COVID-19 has severely impacted older populations and strained healthcare resources, with many patients requiring long periods of hospitalization. Reducing the hospital length of stay (LOS) reduces patient and hospital burden. Given that adverse drug reactions are known to prolong LOS, unmanaged pharmacogenomic risk and drug interactions among COVID-19 patients may be a risk factor for longer hospital stays.

Objective: The objective of this study was to determine if pharmacogenomic and drug interaction risks were associated with longer lengths of stay among high-risk patients hospitalized with COVID-19.

Design: Retrospective cohort study of medical and pharmacy claims

Setting: Administrative database from a large U.S. health insurance company

Participants: Medicare Advantage members with a first COVID-19 hospitalization between January 2020 and June 2020, who did not die during the stay.

Exposures: (1) Pharmacogenetic interaction probability (PIP) of $\leq 25\%$ (low), 26%–50% (moderate), or $> 50\%$ (high), which indicate the likelihood that one or more clinically actionable gene-drug or gene-drug-drug interactions would be identified with testing; (2) drug-drug interaction (DDI) severity of minimal, minor, moderate, major, or contraindicated, which indicate the severity of an interaction between two or more active medications.

Main Outcomes and Measures: The primary outcome was hospital length of stay. Results were stratified by hierarchical condition categories (HCC) counts and chronic conditions.

Results: A total of 6,025 patients hospitalized with COVID-19 were included in the study. Patients with moderate or high PIP were hospitalized for 9% (CI: 4%–15%; $p < 0.001$) and 16% longer (CI: 8%–24%; $p < 0.001$), respectively, compared to those with low PIP, whereas RAF score was not associated with LOS. High PIP was significantly associated with 12%–22% longer lengths of stay compared to low PIP in patients with hypertension, hyperlipidemia, diabetes, or COPD. Finally, among patients with 2 or 3 HCCs, a 10% longer length of stay was

observed among patients with moderate or more severe DDI compared to minimal or minor DDI.

Conclusions and Relevance: Proactively mitigating pharmacogenomic risk has the potential to reduce length of stay in patients hospitalized with COVID-19 especially those with COPD, diabetes, hyperlipidemia, and hypertension.

Introduction

Hospitalizations represent nearly one-third of all U.S. healthcare expenditures.¹ Patient length of stay (LOS) is a longstanding measure of hospital efficiency as longer LOS is associated with greater resource utilization and higher costs.^{2–5} Among many factors associated with longer LOS are adverse drug reactions (ADRs), which are preventable with appropriate medication management.^{6–8} Patient risk factors for ADR are inappropriate polypharmacy as well as harboring genetic variants that affect medication response. Pharmacogenomics-guided medication management could therefore reduce both ADRs and LOS. Studies suggest that >99% of individuals harbor at least one variant associated with an atypical drug response and 24% of individuals may currently take a drug to which they may have an atypical response.^{9–11} Given that greater pharmacogenomic variant burden has been associated with longer LOS,¹² unmanaged pharmacogenomic risk may be an intervenable vulnerability for reducing LOS among high-risk patients.

Population ADR risk management could benefit hospital systems at any time and may benefit hospitals even more so when there is additional population-wide stress on the hospital system, such as the COVID-19 pandemic. The COVID-19 pandemic placed unprecedented demands for hospitals across the globe, and patient demand for hospitalization exceeded hospital resources in several regions.^{13–17} In the US, roughly half of those hospitalized with COVID-19 have been Medicare and Medicare Advantage beneficiaries and the majority of these beneficiaries have been hospitalized for more than 5 days.^{18,19} Medication management interventions may especially help the Medicare population as 54% of patients 65 and older report taking four or more prescription drugs daily.²⁰ This increases their risk for ADR-related hospitalization, which is reported to be 4x greater among patients 65 years of age or older compared to younger patients.²¹ Further, polypharmacy is a reported risk factor for developing COVID-19.²² Thus, hospitalized COVID-19 patients may be at heightened risk for ADR.

A recent study found that nearly 90% of patients hospitalized with COVID-19 were found to have at least one medication order with pharmacogenomic guidance and nearly one-quarter had orders for 4 or more actionable medications.²³ However, it is not clear whether pharmacogenomic risk or drug-drug interaction risk affects LOS among COVID-19 patients. To evaluate the impact of pharmacogenomic risk on LOS among high-risk patients, we conducted a retrospective analysis of administrative medical and pharmacy claims among Medicare Advantage members hospitalized with COVID-19. The main objective of this study was to determine if pharmacogenomic or drug-drug interaction (DDI) risk among Medicare beneficiaries hospitalized with COVID-19 was associated with LOS. We further examined this potential association by the number of diagnosed chronic conditions as well as four specific chronic conditions: chronic obstructive pulmonary disease (COPD), diabetes, hyperlipidemia, and hypertension.

Methods

Data Source and Study Population

Data were obtained from an administrative database of medical and pharmacy claims from a large U.S. health insurance company. The claims include the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, the National Drug Codes (NDC), patient demographic data, and other information. The de-identified data used in this study were granted a waiver of authorization by the institutional review board of the UnitedHealth Group Office of Human Research Affairs.

Claims data for 10,206 Medicare Advantage members admitted to a hospital with COVID-19 between January 1, 2020 and June 30, 2020 were reviewed. COVID-19 diagnoses were identified through SARS-CoV-2 lab test records indicated by the Logical Observation Identifiers Names and Codes (LOINC) organization's guidance for mapping SARS-CoV-2 and COVID-19-related LOINC terms.²⁴ Test information provided via LOINC terms indicated the test type (antibody, RT-PCR, etc.) as well as the test result (detected, not detected, not given/cancelled). Suspected COVID-19 inpatient cases were manually reviewed daily by clinical staff via clinical notes to determine an individual's COVID-19 status, flagging it as either negative, confirmed, presumed positive, or needing clinical review. All findings except for confirmed status were reviewed daily. Only patients' first COVID-19 admission was included and evaluated, and patients who died during their hospital stay (n=1,604, or 16% of patients reviewed) were excluded from the study to remove potential confounders. Only patients continuously enrolled in Medicare Advantage Prescription Drug plans for at least 12 months prior to the index COVID-19 admission were eligible for inclusion.

Independent and Outcome Variables

The primary independent variables were pharmacogenetic interaction probability (PIP) and DDI severity as determined by Invitae's YouScript clinical decision support tool. PIP is the probability that pharmacogenomic testing of 14 genes (*CYP2C19*, *CYP2C9*, *CYP2D6*, *CYP3A4*, *CYP3A5*, *CYP2B6*, *CYP4F2*, *DPYD*, *HLA-B*57:01*, *IFNL3*, *SLCO1B1*, *TPMT*, *UGT1A1*, and *VKORC1*) will result in the detection of one or more clinically significant pharmacogenomic interactions involving one or more medications on the patient's current medication list. PIP was calculated based on publicly available phenotype prevalence data in the U.S. population and pharmacogenomic interaction data, which encompasses clinically actionable drug-drug or drug-drug-gene interactions in CPIC Guidelines and FDA labeling. More robust descriptions of

YouScript are available in US patents.^{25–27} PIP was categorized into the following: 1) low (PIP ≤ 25%), 2) moderate, (PIP 26%–50%); and 3) high (PIP >50%).

DDI indicates the potential for adverse interactions among 2 or more medications prescribed to a patient, irrespective of the patient's pharmacogenomic profile. DDI severity was measured on an ordinal scale of increasing severity: minimal, minor, moderate, major, and contraindicated, with moderate or higher being tied to evidence indicating a need to consider changing a drug or dose. Among patients with multiple DDIs in their drug regimen, only the most severe DDI was used in this study.

All medications active or prescribed within 30 days prior to and during the first COVID-19 admission were screened for PIP and DDIs. Other independent variables were age, gender, race, residential location, median income, risk adjustment factor (RAF), HCC, and Special Needs Plan (SNP) type. RAF scores and HCC, which are measures of disease burden used to determine likely need for medical care, were based on the one-year window prior to the patient's admission month. HCC are simplified diagnosis categories that are constructed using a standardized ICD-10 code mapping determined by the Centers for Medicare and Medicaid Services (CMS). HCC counts indicate the number of chronic conditions and were categorized as 0 or 1, 2 or 3, 4 or 5, or 6 or more, following previously reported CMS categorizations.²⁸ HCC, along with demographic data, were used in an algorithm to assign an RAF score, which is a measure of patient complexity.²⁹ SNPs are Medicare plan types restricted to individuals with specific diseases or characteristics. SNP types were (1) chronic conditions SNP (C-SNP), for individuals with severe or disabling chronic conditions; (2) dual-eligible SNP (D-SNP), for individuals entitled to both Medicare and state Medicaid; and (3) institutional SNP (I-SNP), for individuals who need or are expected to need services in a long-term care skilled nursing facility

or similar high-level care facility for 90 days or longer.³⁰ The outcome variable of interest was LOS during the first COVID-19 admission.

Statistical Analysis

Zero-truncated negative binomial analyses were used to assess the effects of independent variables on LOS. Two sets of analyses were carried out. The first focused on the entire cohort and included the following models: (i) the baseline model that accounted for age, gender, PIP and DDI; and (ii) the regression model that adjusted for the variables identified by least absolute shrinkage and selection operator (LASSO) as covariates with strong association with LOS.³¹ The second set of analyses were subgroup analysis to limit the effects of underlying disease through model fitting and variable selection for each of the following:

- (1) patients stratified by HCC counts (i.e. number of chronic conditions);
- (2) patients stratified by each of the following chronic conditions regardless of other comorbidities: (i) COPD, (ii) diabetes, (iii) hyperlipidemia, and (iv) hypertension.

In both sets of analyses, the point and confidence-interval estimate of the rate ratios and the corresponding *P*-values resulting from the fitted models were obtained. Statistical significance was set at $P < 0.05$. Additionally, descriptive statistics were applied to profile the study population, including count, percentage, mean, and standard deviation (SD). All analyses were conducted using the statistical computing software R version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria).³²

Results

A cohort of 6,025 individuals met all inclusion criteria, including hospitalization with COVID-19 and 12-month continuous Medicare Advantage coverage (Figure 1). Most patients were female (61%), had a mean age of 77 years (SD, 11 years), were of white (non-Hispanic) ancestry

(62%), lived in urban areas (47%), and had an average median household income of \$63,027 (SD, \$17,435) (Table 1). One-third of patients were enrolled in an I-SNP (34%), and 76% had 2 or more chronic conditions. More than half of the study population had hyperlipidemia (58%) or diabetes (52%).

Overall, 42% (2,511 of 6,025) of patients had a moderate or high PIP (Table 1), indicating that among these patients, there was a >25% chance that pharmacogenomic testing would reveal a clinically significant gene-drug or gene-drug-drug interaction. Further, 48% (2,915 of 6,025) had a moderate, major, or contraindicated DDI. Nearly one quarter (24%) of patients were prescribed metoprolol, a beta blocker associated with a minimum PIP of 46% (eTable 1). Other frequently prescribed drugs associated with moderate or high PIP were proton-pump inhibitors pantoprazole (12% of patients) and omeprazole (9%), and serotonin-reuptake inhibitors escitalopram (6%) and citalopram (3%) (eTable 1).

Patients were hospitalized for a mean of 13 days (SD, 11 days) (Table 1). Patients with moderate or high PIP were hospitalized for at least one day longer on average compared to those with low PIP, while LOS for patients with moderate, major, or contraindication DDI was similar to those with minimal or minor DDI (Figure 2 and eTable 2). In unadjusted analyses, the LOS for patients with moderate and high PIP were 9% (CI: 4%–15%; $P<0.001$) and 16% longer (CI: 8%–24%; $P<0.001$), respectively, compared to those with low PIP (eTable 3). Moreover, the LOS for male patients was 8% longer (CI: 3%–13%; $P=0.001$) compared to female patients, and for each one-year age increment, the expected LOS was 0.5% longer (CI: 0.3%–0.7%; $P<0.001$).

Among the entire cohort, adjusting for potential confounders did not attenuate the association between PIP and LOS (Table 2). Notably, across all patients, moderate and high PIP scores

were significant predictors of LOS but RAF score was not (eTable 6). When patients were stratified by HCC count, PIP was significantly associated with LOS among all patient groups except those with 2 or 3 conditions (Table 2). In particular, among patients with 0 or 1, or 4 or 5 conditions, those with moderate PIP had 15% (CI: 4%–28%; $P=0.007$) and 13% (CI: 2%–25%; $P=0.019$) longer LOS, respectively, compared to those with low PIP. Moreover, among patients with 0 or 1, or 6 or more conditions, those with high PIP had 39% (CI: 15%–67%; $P<0.001$) and 16% (CI: 3%–31%; $P=0.014$) longer LOS, respectively, compared to those with low PIP.

Varying associations were observed for LOS, HCC count, and DDI. Among patients with 0 or 1 HCC, those with moderate or greater DDI had a 9% shorter LOS (CI: 0–18%; $P=0.045$) compared to those with minimal or minor DDI (Table 2). Among patients with 2 or 3 HCC, those with moderate or more severe DDI had 10% longer LOS (CI: 2–18%; $P=0.010$) compared to those with minimal or minor DDI. Lastly, across all HCC categories, enrollment in an I-SNP was associated with a 23%–34% shorter LOS compared to those not enrolled in I-SNP (eTables 6–10).

To explore the impact of individual comorbidities on LOS, patients were stratified by four pre-existing chronic conditions: COPD, diabetes, hyperlipidemia, and hypertension. Patients with high PIP most frequently had hyperlipidemia (eTable 11). Within each chronic condition subpopulation (controlled for the other chronic conditions), patients with high PIP were hospitalized 12%–22% longer compared to those with low PIP (Table 2). In particular, among patients with hypertension, those with high PIP were hospitalized 2.5 days longer than those with low PIP (Table 3). Moreover, patients diagnosed with hyperlipidemia or COPD who had moderate PIP had longer LOS by 8% (CI: 2%–15%; $P=0.013$) and 13% (CI: 3%–24%; $P=0.009$), respectively, compared to those with low PIP (Table 2).

When considering the potential impact of DDI on LOS, we found that patients diagnosed with diabetes and at least moderate or more severe DDI had 7% longer LOS (CI: 1%–13%; $P=0.031$) compared to those with minimal or minor DDI (Table 2). Lastly, patients in each chronic condition group who were enrolled in I-SNP had a 25%–29% shorter LOS than those not enrolled (eTables 12–15).

Discussion

In this study, we showed that greater pharmacogenomic risk was associated with longer LOS among Medicare Advantage members hospitalized with COVID-19. In particular, high PIP patients, who have a 50% or greater likelihood of harboring a genetics-driven atypical response to current medications, were hospitalized for almost two days longer than those with low PIP. Given the known associations between ADRs and LOS,⁸ our findings suggest that incorporating pharmacogenomic testing into clinical management of high-risk COVID-19 patients may shorten hospital LOS. Critically, to potentially reduce LOS, testing would have to occur prior to admission to allow for testing results to be incorporated into a patient's medication management.

In a novel pandemic such as the COVID-19 crisis, the sudden and intense demands on hospitals present a clear need to reduce patient LOS. Should proactive pharmacogenomics-informed medication management for COVID-19 patients successfully reduce LOS, even non-COVID patients could benefit by reducing the burden on overwhelmed healthcare systems that have delayed some patient care.^{16,33–35} In addition, pharmacogenomic intervention could reduce COVID-19 healthcare costs. Estimating the potential cost savings from a reduction in LOS is challenging; however, recent data show that the average Medicare payment per COVID-19 hospitalization is \$23,587,¹⁸ which is \$8,688 higher than the average Medicare Advantage hospitalization (\$14,900).³⁶ Considering the higher cost associated with complex COVID-19

patients, pharmacogenomic-informed medication management of Medicare beneficiaries could result in substantial savings for patients, hospitals, and the Medicare program.

Overall, we found that almost half of Medicare Advantage members hospitalized with COVID-19 could benefit from improved medication management, as 42% had a moderate or high PIP and 48% had a moderate, major, or contraindicated DDI for current medications.^{9–11} Further, despite mandates to flag DDIs in electronic health records and pharmacy systems, we found that one-third of our cohort was prescribed medications for which risks likely exceeded benefits. Thus, comprehensive medication management is underutilized among Medicare members, leaving many at risk for ADRs. Incorporating pharmacy expertise into the clinical management of patients could reduce this risk as pharmacist participation has been shown to reduce ADRs, LOS, and mortality.³⁹

Several findings in our subpopulation analyses warrant further study. When patients were stratified by number of chronic conditions, patients with 0 or 1 HCC and high PIP had a greater LOS increase than those with 6 or more HCC (39% vs 16% increase), which may be due to uncontrolled confounders such as severity of COVID-19 infection. In addition, we did not observe a significant association between PIP and LOS among patients with 2 or 3 chronic conditions despite finding a significant association for all other HCC counts. A larger sample size may reveal significant findings for those with 2 or 3 HCC and possibly identify additional confounders. In addition, the finding that patients with 0 or 1 HCC and more severe DDI had shorter LOS compared to those with less severe DDI requires further study that examines the specific medications used by those patients. Separately, for each specific chronic condition (COPD, diabetes, hyperlipidemia, and hypertension), we found patients with high PIP had significantly longer LOS compared to those with low PIP. Further research may explore the impact of pharmacogenomic risk and ADRs among COVID-19 patients with these comorbidities.

Finally, in both subpopulation analyses, I-SNP enrollment was associated with shorter LOS. This may be a result of potential ADRs receiving more attention in institutional settings, or conversely, an effect of more expedient discharge due to enhanced care coordination with institutional settings.

LOS is a long-standing concern for healthcare organization performance, patient outcomes, and expenditures.^{40,41,42} Although this study focused on COVID-19, population-based pharmacogenomic testing that improves medication management could broadly reduce ADRs, which are reported to cost the US \$528 billion per year, exceeding the costs associated with any major disease or the actual drugs prescribed.⁴³ A one-time test could aid medication optimization and potentially reduce healthcare costs throughout each patient's life. In addition, future research should further explore the potential for PIP to predict LOS, as moderate and high PIP were both significant predictors of LOS whereas RAF score, a metric used by CMS for benchmarking expenditures and allocating payments to healthcare providers, was not (eTable 6).

Limitations

Limitations to this study include that although this study showed an association between PIP and increased LOS, it was not a study demonstrating that increased LOS among COVID-19 patients was a direct result of adverse drug events that could have been prevented by proactive pharmacogenomic testing. Future studies with large, controlled cohorts are needed to demonstrate the impact of pharmacogenomics-guided medication management on hospital LOS. In addition, the analyses did not account for some potential confounders such as severity of COVID-19, medication regimen complexity (including the types and counts of prescribed drugs, medication dosage or frequency), or patient kidney or hepatic function. A general limitation of observational studies using claims data is that the presence of a code does not

guarantee that a patient has been diagnosed or has received or taken a prescribed medication.

Finally, our findings may have been affected by a survivor bias arising from the exclusion of patients who died during the study period.

Conclusions

Among otherwise risk-matched patients with COVID-19, moderate or high pharmacogenomic risk was associated with longer LOS. Addressing pharmacogenomic risk prior to COVID-19 hospitalization or other serious disease may reduce LOS, decrease healthcare costs, and improve risk predictions in Medicare members, especially those with COPD, diabetes, hyperlipidemia, or hypertension.

Acknowledgements

Taryn Hall had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

The authors thank Kathy Tzeng of UnitedHealth Group (UHG) for the initial development of this project, Nicolas Moyer of Invitae for assisting with analyses, and Elaine Preimesberger of UHG and Melinda Tran of Invitae for their review and feedback on this draft.

Authors KA, CM, CS, and SR are employees of genetic testing company Invitae. Authors KVT, GOM, JR, BM, YG, ETE, and TOH are employees of UHG.

Figures Legends

Figure 1. Selection of Study Patients.

Figure 2.

Figure 2. Length of stay by pharmacogenomic risk among Medicare Advantage members hospitalized with COVID-19.

Average length of stay (LOS) in days among the entire cohort and subpopulations stratified by HCC count or chronic conditions was compared by (A) pharmacogenomic interaction probability (PIP) and (B) drug-drug interaction (DDI). Error bars show 95% confidence intervals.

PIP: pharmacogenetic interaction probability; HCC: hierarchical condition categories; COPD: chronic obstructive pulmonary disease.

Tables

Table 1. Characteristics of hospitalized COVID-19 Medicare Advantage members

Variable	Category	Value
<i>Demographic / socioeconomic factors</i>		
Gender	Female, No. (%)	3,653 (61)
Age	Mean (SD)	77 (11)
Race	White (non-Hispanic), No. (%)	3,753 (62)
	Black (non-Hispanic), No. (%)	1,791 (30)
	Hispanic / Latino, No. (%)	191 (3)
	Other, No. (%)	140 (2)
	Asian / Pacific Islander, No. (%)	99 (2)
	Unknown, No. (%)	51 (1)
Residential location	Urban, No. (%)	2,853 (47)
	Suburban, No. (%)	2,200 (37)
	Rural, No. (%)	972 (16)
Median income	Mean (SD)	\$63,027 (\$17,435)
<i>Plan and clinical characteristics</i>		
C-SNP	Enrolled, No. (%)	268 (4)
D-SNP	Enrolled, No. (%)	332 (6)
I-SNP	Enrolled, No. (%)	2,061 (34)
HCC count	0 or 1, No. (%)	1,460 (24)
	2 or 3, No. (%)	1,991 (33)
	4 or 5, No. (%)	1,182 (20)
	6 or more, No. (%)	1,392 (23)
Chronic conditions	COPD, No. (%)	1,450 (24)
	Diabetes, No. (%)	3,104 (52)
	Hyperlipidemia, No. (%)	3,499 (58)
	Hypertension, No. (%)	1,902 (32)
COVID-19 hospitalization (in days)	Mean LOS (SD)	12.6 (11)
PIP	Low, ≤25%, No. (%)	3,514 (58)
	Moderate, 26%–50%, No. (%)	1,784 (30)
	High, >50%, No. (%)	727 (12)
DDI	Minimal or minor, No. (%)	3,110 (52)
	Moderate, No. (%)	983 (16)
	Major, No. (%)	1,542 (25)
	Contraindicated, No. (%)	390 (7)

C-SNP: chronic conditions special needs plan (SNP); D-SNP: dual-eligible SNP; I-SNP: institutional SNP; HCCs: hierarchical conditions categories; LOS: length of stay; PIP: pharmacogenetic interaction probability; DDI: drug-drug interaction

Table 2. Expected length-of-stay ratios by pharmacogenetic risk and drug-drug interactions among patients by HCC count and chronic conditions.

Population	Moderate PIP (26% to 50%)*		High PIP (>50%)*		Moderate, Major, or Contraindicated DDI**	
	Rate ratio (95% CI)	P-value	Rate ratio (95% CI)	P-value	Rate ratio (95% CI)	P-value
Total cohort	1.09 (1.04, 1.14)	< 0.001	1.16 (1.09, 1.24)	< 0.001	1.04 (1.00, 1.09)	0.066
HCC count						
Any	1.09 (1.04, 1.14)	< 0.001	1.16 (1.09, 1.24)	< 0.001	1.04 (1.00, 1.09)	0.066
0 or 1	1.15 (1.04, 1.28)	0.007	1.39 (1.15, 1.67)	< 0.001	0.91 (0.82, 1.00)	0.045
2 or 3	1.03 (0.95, 1.11)	0.522	1.08 (0.96, 1.21)	0.204	1.10 (1.02, 1.18)	0.010
4 or 5	1.13 (1.02, 1.25)	0.019	1.13 (1.00, 1.29)	0.057	1.07 (0.97, 1.17)	0.179
6 or more	1.08 (0.98, 1.18)	0.112	1.16 (1.03, 1.31)	0.014	1.01 (0.93, 1.11)	0.786
Chronic conditions						
COPD	1.13 (1.03, 1.24)	0.009	1.18 (1.05, 1.34)	0.006	1.01 (0.93, 1.10)	0.796
Diabetes	1.05 (0.99, 1.12)	0.119	1.15 (1.05, 1.25)	0.002	1.07 (1.01, 1.13)	0.031
Hyperlipidemia	1.08 (1.02, 1.15)	0.013	1.12 (1.02, 1.22)	0.014	1.05 (0.99, 1.11)	0.096
Hypertension	1.03 (0.95, 1.12)	0.478	1.22 (1.10, 1.35)	< 0.001	1.02 (0.95, 1.1)	0.522

*0-25% as baseline; **minimal or minor as baseline

HCCs: hierarchical conditions categories; PIP: pharmacogenetic interaction probability; DDI: drug-drug interaction; COPD: chronic obstructive pulmonary disease. Significance was set at $P < 0.05$.

Table 3. Distribution of length of stay among patients hospitalized with COVID-19 by chronic condition and pharmacogenomic or drug-drug interaction risk

Chronic condition	Total subpopulation, mean LOS (95% CI)	Mean LOS (95% CI) by PIP			Mean LOS (95% CI) by DDI	
		Low (≤25%)	Moderate (26–50%)	High (>50%)	Minimal or minor	Moderate, major, or contraindicated
COPD	13.0 (12.4, 13.6)	12.1 (11.4, 12.8)	13.9 (12.8, 15)	14.4 (12.8, 16)	13.1 (12.1, 14.1)	12.9 (12.2, 13.6)
Diabetes	12.5 (12.1, 12.9)	12 (11.5, 12.5)	12.8 (12.1, 13.5)	13.6 (12.6, 14.6)	12.3 (11.8, 12.8)	12.7 (12.2, 13.2)
Hyperlipidemia	12.7 (12.3, 13.1)	12.2 (11.7, 12.7)	13.3 (12.6, 14)	13.6 (12.5, 14.7)	12.5 (12, 13)	12.9 (12.4, 13.4)
Hypertension	13.0 (12.5, 13.5)	12.5 (11.8, 13.2)	12.9 (12.1, 13.7)	15 (13.6, 16.4)	12.9 (12.2, 13.6)	13.1 (12.4, 13.8)

LOS: length of stay; PIP: pharmacogenomic interaction probability; DDI: drug-drug interaction.

References

1. Weiss AJ, Elixhauser A. Overview of Hospital Stays in the United States, 2012: Statistical Brief #180. In: *Healthcare Cost and Utilization Project (HCUP) Statistical Briefs*. Agency for Healthcare Research and Quality (US); 2014.
<https://www.ncbi.nlm.nih.gov/pubmed/25506966>
2. Bueno H, Ross JS, Wang Y, et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. *JAMA*. 2010;303(21):2141-2147. doi:10.1001/jama.2010.748
3. Lu M, Sajobi T, Lucyk K, Lorenzetti D, Quan H. Systematic review of risk adjustment models of hospital length of stay (LOS). *Med Care*. 2015;53(4):355-365. doi:10.1097/MLR.0000000000000317
4. Salim SA, Elmaraezy A, Pamarthy A, Thongprayoon C, Cheungpasitporn W, Palabindala V. Impact of hospitalists on the efficiency of inpatient care and patient satisfaction: a systematic review and meta-analysis. *J Community Hosp Intern Med Perspect*. 2019;9(2):121-134. doi:10.1080/20009666.2019.1591901
5. Ward C, Patel V, Elsaid MI, Jaisinghani P, Sharma R. A case-control study of length of stay outliers. *Am J Manag Care*. 2021;27(3):e66-e71. doi:10.37765/ajmc.2021.88600
6. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA*. 1998;279(15):1200-1205. doi:10.1001/jama.279.15.1200
7. Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. *J Pharmacol Pharmacother*. 2013;4(Suppl 1):S73-S77. doi:10.4103/0976-500X.120957
8. Formica D, Sultana J, Cutroneo PM, et al. The economic burden of preventable adverse drug reactions: a systematic review of observational studies. *Expert Opin Drug Saf*. 2018;17(7):681-695. doi:10.1080/14740338.2018.1491547
9. Ji Y, Skierka JM, Blommel JH, et al. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. *J Mol Diagn*. 2016;18(3):438-445. doi:10.1016/j.jmoldx.2016.01.003
10. Chanfreau-Coffinier C, Hull LE, Lynch JA, et al. Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users. *JAMA Netw Open*. 2019;2(6):e195345. doi:10.1001/jamanetworkopen.2019.5345
11. McInnes G, Lavertu A, Sangkuhl K, Klein TE, Whirl-Carrillo M, Altman RB. Pharmacogenetics at Scale: An Analysis of the UK Biobank. *Clin Pharmacol Ther*. Published online November 25, 2020. doi:10.1002/cpt.2122
12. Finkelstein J, Zhang F, Cabrera M. Association Between Number of Actionable Pharmacogenetic Variants and Length of Hospital Stay. *Stud Health Technol Inform*. 2020;272:195-198. doi:10.3233/SHTI200527

13. Shadmi E, Chen Y, Dourado I, et al. Health equity and COVID-19: global perspectives. *Int J Equity Health*. 2020;19(1):104. doi:10.1186/s12939-020-01218-z
14. Lal A, Erondur NA, Heymann DL, Gitahi G, Yates R. Fragmented health systems in COVID-19: rectifying the misalignment between global health security and universal health coverage. *Lancet*. 2021;397(10268):61-67. doi:10.1016/S0140-6736(20)32228-5
15. Grasselli G, Pesenti A, Cecconi M. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response. *JAMA*. 2020;323(16):1545-1546. doi:10.1001/jama.2020.4031
16. Iacobucci G. Covid-19: all non-urgent elective surgery is suspended for at least three months in England. *BMJ*. 2020;368:m1106. doi:10.1136/bmj.m1106
17. Kerlin MP, Costa DK, Davis BS, Admon AJ, Vranas KC, Kahn JM. Actions taken by US hospitals to prepare for increased demand for intensive care during the first wave of COVID-19: A national survey. *Chest*. Published online March 11, 2021. doi:10.1016/j.chest.2021.03.005
18. Centers for Medicare and Medicaid Services. Preliminary Medicare COVID-19 data Snapshot - March 19, 2021. Accessed April 27, 2021. <https://www.cms.gov/research-statistics-data-systems/preliminary-medicare-covid-19-data-snapshot>
19. Di Fusco M, Shea KM, Lin J, et al. Health outcomes and economic burden of hospitalized COVID-19 patients in the United States. *J Med Econ*. 2021;24(1):308-317. doi:10.1080/13696998.2021.1886109
20. Data note: Prescription drugs and older adults. Published August 9, 2019. Accessed January 27, 2021. <https://www.kff.org/health-reform/issue-brief/data-note-prescription-drugs-and-older-adults/>
21. Beijer HJM, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. *Pharm World Sci*. 2002;24(2):46-54. doi:10.1023/a:1015570104121
22. McQueenie R, Foster HME, Jani BD, et al. Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort. *PLoS One*. 2020;15(8):e0238091. doi:10.1371/journal.pone.0238091
23. Stevenson JM, Alexander GC, Palamuttam N, Mehta HB. Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID-19: A Retrospective Multicenter Study in the United States. *Clin Transl Sci*. 2021;14(1):153-162. doi:10.1111/cts.12919
24. SARS-CoV-2 and COVID-19 related LOINC terms. Accessed February 26, 2021. <https://loinc.org/sars-cov-2-and-covid-19/>
25. Patterson RD, Oesterheld J, Coleman HC. Genetic data analysis and database tools. *US Patent*. Published online November 13, 2012. Accessed January 11, 2021. <https://patentimages.storage.googleapis.com/bf/3c/03/9991cfd0b41213/US8311851.pdf>
26. Coleman HC, Oesterheld J, Patterson RD. Genetic data analysis and database tools. *US*

- Patent*. Published online January 17, 2012. Accessed January 11, 2021. <https://patentimages.storage.googleapis.com/25/02/74/0495cac7195d3a/US8099298.pdf>
27. Coleman HC, Patterson RD, Oesterheld J, Pany RV, Ashcraft K. Systems and methods for quantification and presentation of medical risk arising from unknown factors. *US Patent*. Published online May 30, 2019. Accessed January 11, 2021. <https://patentimages.storage.googleapis.com/2b/e7/da/75f4be1d8818f2/US20190164637A1.pdf>
 28. Office of Enterprise Data and Analytics, Centers for Medicare & Medicaid Services (CMS). Chronic Conditions among Medicare Beneficiaries. Published 2018. Accessed January 27, 2021. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Chronic-Conditions/Chartbook_Charts
 29. Hierarchical condition category coding. Accessed January 29, 2021. <https://www.aafp.org/family-physician/practice-and-career/getting-paid/coding/hierarchical-condition-category.html>
 30. Special Needs Plans. Accessed January 29, 2021. <https://www.cms.gov/Medicare/Health-Plans/SpecialNeedsPlans>
 31. Regression Shrinkage and Selection via the Lasso. *Journal of the Royal Statistical Society, Series B (Methodological)*. 1996;58(1). <https://www.jstor.org/stable/2346178?seq=1>
 32. R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria. URL; 2014. <http://www.R-project.org/>
 33. Moreno R, Díez J-L, Diarte J-A, et al. Consequences of canceling elective invasive cardiac procedures during Covid-19 outbreak. *Catheter Cardiovasc Interv*. Published online December 17, 2020. doi:10.1002/ccd.29433
 34. Ueda M, Martins R, Hendrie PC, et al. Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal. *J Natl Compr Canc Netw*. Published online March 20, 2020;1-4. doi:10.6004/jnccn.2020.7560
 35. Bennett S, Søreide K, Gholami S, et al. Strategies for the delay of surgery in the management of resectable hepatobiliary malignancies during the COVID-19 pandemic. *Curr Oncol*. 2020;27(5):e501-e511. doi:10.3747/co.27.6785
 36. Medicare Advantage Versus the Traditional Medicare Program: Costs of Inpatient Stays, 2009-2017 #262. Accessed March 19, 2021. <https://www.hcup-us.ahrq.gov/reports/statbriefs/sb262-Medicare-Advantage-Costs-2009-2017.jsp>
 37. Luzum JA, Pakyz RE, Elsey AR, et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and metrics of pharmacogenetic implementations across diverse healthcare systems. *Clin Pharmacol Ther*. 2017;102(3):502-510. doi:10.1002/cpt.630
 38. Roden DM, Van Driest SL, Mosley JD, et al. Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome. *Clin Pharmacol Ther*. 2018;103(5):787-794. doi:10.1002/cpt.1035

39. Lee H, Ryu K, Sohn Y, Kim J, Suh GY, Kim E. Impact on Patient Outcomes of Pharmacist Participation in Multidisciplinary Critical Care Teams: A Systematic Review and Meta-Analysis. *Crit Care Med*. 2019;47(9):1243-1250. doi:10.1097/CCM.0000000000003830
40. Williams TA, Ho KM, Dobb GJ, et al. Effect of length of stay in intensive care unit on hospital and long-term mortality of critically ill adult patients. *Br J Anaesth*. 2010;104(4):459-464. doi:10.1093/bja/aeq025
41. Marfil-Garza BA, Belaunzarán-Zamudio PF, Gúlias-Herrero A, et al. Risk factors associated with prolonged hospital length-of-stay: 18-year retrospective study of hospitalizations in a tertiary healthcare center in Mexico. *PLoS One*. 2018;13(11):e0207203. doi:10.1371/journal.pone.0207203
42. Chang AM, Lin A, Fu R, McConnell KJ, Sun B. Associations of Emergency Department Length of Stay With Publicly Reported Quality-of-care Measures. *Acad Emerg Med*. 2017;24(2):246-250. doi:10.1111/acem.13102
43. Watanabe JH, McInnis T, Hirsch JD. Cost of Prescription Drug-Related Morbidity and Mortality. *Ann Pharmacother*. 2018;52(9):829-837. doi:10.1177/1060028018765159